Metastatic cancer is a cagey adversary, a shape- and form-changing disease that can be understood only by following its dynamics at a cellular level. Most tests are based upon fixed assumptions of what cancer looks like, however, they come up short. For that reason, Epic Sciences chose a research road less traveled, a bias-free approach that looks at all the cells in a non-invasive blood sample, and thus sees those rare cells that others miss.
Every cancer is as unique as the person who carries it. So the tests that diagnose and monitor the illness must be eminently personal, proven and precise.
If you can’t see the problem, you can’t solve it.
Maximizing a revolutionary component: Certainty.
Epic’s new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer. This test requires but a simple blood draw and is unambiguous, giving doctors a clearer picture of a patient's metastatic disease, thus allowing them to proceed with confidence and certainty while sparing patients the anxiety associated with the uncertainty of an uninformed choice.
A bias-free vision of cancer research.
At Epic Sciences, we develop clinical solutions that accelerate drug development and provide valuable insights into the dynamics of cancer growth, evolution and heterogeneity. Our AR-V7 CTC test, for example, has demonstrated predictive clinical utility for prostate cancer. It’s but one example of our dedication to the development of proven tests to guide therapy selection across the most impactful drug classes in oncology.
AR-V7 status predicts abiraterone, enzalutamide response in mCRPC
The PROPHECY study represents a multicenter effort that provides prospective, blinded clinical validation around such an approach and suggests that both the JHU CTC AR-V7 mRNA assay and the Epic CTC nuclear-specific AR-V7 protein assay provide clinical utility around the anticipated outcomes with therapy.
Test Predicts Resistance to Hormonal Therapy in Prostate Cancer - Validation study confirms assist in decision-making
A blood test that measures the spliced variant of an androgen receptor called AR-V7 in circulating tumor cells successfully predicted resistance to commonly used hormonal therapy agents in advanced prostate cancer, a validation study confirmed.
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences' Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer
Epic Sciences, Inc. (Epic) today announced the publication of results from a multicenter prospective trial validating the biomarker AR-V7 (androgen receptor splice variant-7) as a predictor of resistance to anti-androgen therapy in men with metastatic castration-resistant prostate cancer (mCRPC). Data from the PROPHECY trial, published in the Journal of Clinical Oncology, demonstrate that detection of AR-V7 in circulating tumor cells (CTCs) in blood is predictive of whether men with mCRPC have become resistant to androgen-receptor signaling (ARS) inhibitors and have a low chance of benefit from further ARS therapy.
CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC
Nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) is a predictive marker of shorter progression-free and overall survival (OS) with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer (mCRPC), according to results from the phase III PROPHECY trial that were published in the Journal of Clinical Oncology.